Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio.
Children's Hospital of Alabama, University of Alabama at Birmingham.
Arthritis Rheumatol. 2018 Jun;70(6):963-970. doi: 10.1002/art.40438. Epub 2018 May 2.
Macrophage activation syndrome (MAS) is a life-threatening complication of systemic juvenile idiopathic arthritis (JIA) and has pathologic similarity to hemophagocytic lymphohistiocytosis (HLH). Intronic variants in UNC13D are found in patients with familial HLH type 3 (FHLH3), but the role of noncoding variants in MAS is unknown. The objective of this study was to identify deep intronic UNC13D variants in patients with MAS.
A custom enrichment library was constructed to sequence a genomic region of ~1 Mb flanking UNC13D in 24 patients with systemic JIA, recurrent MAS, and negative results of prior genetic (exon/coding) testing. The functional consequences of intronic variants were assessed using quantitative polymerase chain reaction in patient-derived peripheral blood mononuclear cells (PBMCs), electromobility shift assay, in vitro transcriptional enhancer assays, and natural killer (NK) cell degranulation assays.
We evaluated a patient with systemic JIA and recurrent MAS in whom a novel functional intronic variant in UNC13D, c.117+143A>G, was observed. This variant occurred in a proposed regulatory region that drives lymphocyte-specific UNC13D expression and is associated with reduced transcript levels in patient PBMCs. This variant also disrupted NF-κB binding to a functional transcriptional enhancer, leading to reduced enhancer activity in vitro. Partial knockdown of UNC13D expression also led to impaired NK cell degranulation. An additional patient was identified with a previously described UNC13D intronic variant, for a total noncoding variant hit rate of 8.3% (2 of 24).
These findings highlight the notion that intronic variants in key regulatory regions may be associated with MAS in patients with systemic JIA and support deep sequencing approaches when causative coding variants are not identified.
巨噬细胞活化综合征(MAS)是一种危及生命的全身幼年特发性关节炎(JIA)并发症,其病理与噬血细胞性淋巴组织细胞增生症(HLH)相似。UNC13D 的内含子变体存在于家族性 HLH 型 3(FHLH3)患者中,但非编码变体在 MAS 中的作用尚不清楚。本研究的目的是鉴定 MAS 患者中 UNC13D 的深内含子变体。
构建了一个定制的富集文库,以对 24 名患有全身 JIA、复发性 MAS 和先前遗传(外显子/编码)检测结果为阴性的患者的 UNC13D 侧翼约 1 Mb 的基因组区域进行测序。使用患者来源的外周血单核细胞(PBMC)中的定量聚合酶链反应、电泳迁移率变动分析、体外转录增强子测定和自然杀伤(NK)细胞脱颗粒测定来评估内含子变体的功能后果。
我们评估了一名患有全身 JIA 和复发性 MAS 的患者,在该患者中观察到 UNC13D 中的新型功能性内含子变体 c.117+143A>G。该变体发生在驱动淋巴细胞特异性 UNC13D 表达的推定调节区域,与患者 PBMC 中的转录本水平降低相关。该变体还破坏了 NF-κB 与功能性转录增强子的结合,导致体外增强子活性降低。UNC13D 表达的部分敲低也导致 NK 细胞脱颗粒受损。另外一名患者被鉴定出 UNC13D 内含子变体,总非编码变体命中率为 8.3%(24 例中有 2 例)。
这些发现强调了关键调节区域的内含子变体可能与全身 JIA 患者的 MAS 相关,并支持在未鉴定出致病编码变体时采用深度测序方法。